Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bevacizumab biosimilar (Innovent Biologics) in Locally Advanced Malignant Solid Neoplasm: NCT07124793 Clinical Landscape Report 2026
16 October 2026
NCT07124793 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Methotrexate Sodium in Psoriasis: CTRI/2025/08/093186 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/08/093186 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Duvax in Alzheimer Disease: NCT07142278 Clinical Landscape Report 2026
16 October 2026
NCT07142278 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab in Mismatch repair-deficient Endometrial Carcinoma: NCT07146919 Clinical Landscape Report 2026
16 October 2026
NCT07146919 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Iparomlimab/Tuvonralimab in Recurrent Cervical Cancer: NCT07141186 Clinical Landscape Report 2026
16 October 2026
NCT07141186 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KS-101(Klotho Sciences) in Alzheimer Disease: NCT07143331 Clinical Landscape Report 2026
16 October 2026
NCT07143331 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chlorophyllin Copper Sodium in Uterine Cervix Adenocarcinoma: CTRI/2025/09/094294 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/09/094294 clinical landscape for Uterine Cervix Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Camrelizumab in Recurrent Cervical Cancer: NCT07143292 Clinical Landscape Report 2026
16 October 2026
NCT07143292 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AV-1980R in Alzheimer Disease: NCT07158905 Clinical Landscape Report 2026
16 October 2026
NCT07158905 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Locally Advanced Malignant Solid Neoplasm: NCT07156253 Clinical Landscape Report 2026
16 October 2026
NCT07156253 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
ASCA-101 in Lung Cancer: NCT07168226 Clinical Landscape Report 2026
16 October 2026
NCT07168226 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trontinemab in Alzheimer Disease: NCT07170150 Clinical Landscape Report 2026
16 October 2026
NCT07170150 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.